Xu S, Song Z, Wang D, Wang E, et al. Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS). BMC Cancer 2025;25:1190.
PMID: 40684089